← Human Trials & Peer-Reviewed Studies
Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study.
Plain-language guide to PMID 16053996 (2005): double-blind randomized controlled trial of Angiotensin II Type 1 Receptor Blockers in 809 subjects.
Key Facts
- PMID
- 16053996
- Journal
- American journal of hypertension
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Nesbitt SD et al. (5 authors)
- DOI
- 10.1016/j.amjhyper.2005.01.021
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II Type 1 Receptor Blockers, published as a randomized controlled trial.
The researchers are presenting the baseline cardiovascular risk factor profile of the 809 subjects randomized in the TROPHY Study.
Who Took Part
According to the abstract, 809 subjects were involved.
By PubMed's age tags, the people studied were middle-aged adults, both men and women.
The TROPHY Study is a 4-year randomized, placebo-controlled, multicenter clinical trial of 809 subjects with high normal blood pressure (BP), which is currently in progress.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.
The subjects were allocated by chance, so the Angiotensin II Type 1 Receptor Blockers group and the comparison group should start out alike.
As a double-blind Angiotensin II Type 1 Receptor Blockers study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Angiotensin II Type 1 Receptor Blockers group a baseline to be compared against.
More than one site took part, so the subjects came from several places.
What Was Measured
Topics PubMed links to this paper include Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Blood Pressure, Body Mass Index, Cluster Analysis, Disease Progression and Hypertension.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II Type 1 Receptor Blockers in 809 subjects.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2005 (American journal of hypertension), a journal based in United States.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.